Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Primary Purpose
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Status
Completed
Phase
Phase 1
Locations
Colombia
Study Type
Interventional
Intervention
Angel Catheter
Sponsored by
About this trial
This is an interventional prevention trial for Pulmonary Embolism focused on measuring Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Central Line Catheter, Vena Cava Filters
Eligibility Criteria
Inclusion Criteria:
- Subject is 18 years and older
Be admitted to the hospital
One of the following two criteria:
Patients with proven deep vein thrombosis (DVT) or pulmonary embolism ( PE), at high risk for pulmonary embolism and under consideration for insertion of a retrievable inferior vena cava (IVC) filter with at least one of the following criteria:
- Contraindications for anticoagulation
- Recurrent PE despite adequate anticoagulation
- Emergency treatment following massive pulmonary embolism
Patients at high risk for developing PE who require but have a temporary or absolute contraindication for prophylaxis with anticoagulation, including:
- Patients with multiple trauma and active or recent bleeding with contraindications to anticoagulation or that require a temporary stop of anticoagulation
- severe head injury with coma
- severe hemorrhagic stroke with coma
- head injury with a long bone fracture
- spinal cord injury with paraplegia or quadriplegia
- multiple (≥2) long bone fractures with pelvic fracture
- multiple (≥4) long bone fractures
- Critically ill patients in the Medical or Surgical Intensive Care Unit with high risk of PE that require but are contraindicated for anticoagulation prophylaxis and will benefit from a temporary filter and a central venous access catheter
- Patients who had recently undergone or are about to undergo a surgical procedure that requires temporary interruption of anticoagulation for Venous Thromboembolism (VTE) and will benefit from a temporary vena cava filter and central
Exclusion Criteria:
- Patient is less than 18 years
- Patient is pregnant or has a positive serum human chorionic gonadotropin (HCG) pregnancy test at baseline visit
- Patient or next legal representative cannot give informed consent
- Patients with anticipated survival < 2 days (catastrophic illness)
- Body mass index greater than 35
- Patient has a pre-existing filter
- Participation in another simultaneous interventional medical investigation or interventional trial.
- Patient has indications for a permanent filter at the time of the initial evaluation
- Patient has an uncontrollable coagulopathy with active bleeding.
- Patient with proven endocarditis or bacteremia
- Patient has hypersensitivity to any of the components of the Angel™ Catheter, specifically Nitinol
- Known acute or chronic thrombotic occlusion of both common femoral veins or iliac veins
- Patient with functioning pelvic renal allograft on the only side available for device insertion
- Patient who will undergo surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted
Sites / Locations
- Clinica las Americas
- Hospital Pablo Tobon Uribe
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Angel Catheter
Arm Description
Outcomes
Primary Outcome Measures
Safety
Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01403090
Brief Title
Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Official Title
A Single Treatment, Open Label, Multicenter, Safety Study of the Angel™ Catheter in Hospitalized Human Subjects With a Temporary Risk of Pulmonary Embolism
Study Type
Interventional
2. Study Status
Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
March 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BiO2 Medical
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The primary endpoint is freedom from serious adverse events (SAE), defined as death, symptomatic pulmonary embolism or major bleeding .
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Keywords
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Central Line Catheter, Vena Cava Filters
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Angel Catheter
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Angel Catheter
Intervention Description
The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
Primary Outcome Measure Information:
Title
Safety
Description
Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is 18 years and older
Be admitted to the hospital
One of the following two criteria:
Patients with proven deep vein thrombosis (DVT) or pulmonary embolism ( PE), at high risk for pulmonary embolism and under consideration for insertion of a retrievable inferior vena cava (IVC) filter with at least one of the following criteria:
Contraindications for anticoagulation
Recurrent PE despite adequate anticoagulation
Emergency treatment following massive pulmonary embolism
Patients at high risk for developing PE who require but have a temporary or absolute contraindication for prophylaxis with anticoagulation, including:
Patients with multiple trauma and active or recent bleeding with contraindications to anticoagulation or that require a temporary stop of anticoagulation
severe head injury with coma
severe hemorrhagic stroke with coma
head injury with a long bone fracture
spinal cord injury with paraplegia or quadriplegia
multiple (≥2) long bone fractures with pelvic fracture
multiple (≥4) long bone fractures
Critically ill patients in the Medical or Surgical Intensive Care Unit with high risk of PE that require but are contraindicated for anticoagulation prophylaxis and will benefit from a temporary filter and a central venous access catheter
Patients who had recently undergone or are about to undergo a surgical procedure that requires temporary interruption of anticoagulation for Venous Thromboembolism (VTE) and will benefit from a temporary vena cava filter and central
Exclusion Criteria:
Patient is less than 18 years
Patient is pregnant or has a positive serum human chorionic gonadotropin (HCG) pregnancy test at baseline visit
Patient or next legal representative cannot give informed consent
Patients with anticipated survival < 2 days (catastrophic illness)
Body mass index greater than 35
Patient has a pre-existing filter
Participation in another simultaneous interventional medical investigation or interventional trial.
Patient has indications for a permanent filter at the time of the initial evaluation
Patient has an uncontrollable coagulopathy with active bleeding.
Patient with proven endocarditis or bacteremia
Patient has hypersensitivity to any of the components of the Angel™ Catheter, specifically Nitinol
Known acute or chronic thrombotic occlusion of both common femoral veins or iliac veins
Patient with functioning pelvic renal allograft on the only side available for device insertion
Patient who will undergo surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos Cadavid, MD
Organizational Affiliation
Hospital Pablo Tobon Uribe
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bladimir Gil, MD
Organizational Affiliation
Clinica Las Americas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinica las Americas
City
Medellin
State/Province
Antioquia
Country
Colombia
Facility Name
Hospital Pablo Tobon Uribe
City
Medellin
State/Province
Antioquia
Country
Colombia
12. IPD Sharing Statement
Learn more about this trial
Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
We'll reach out to this number within 24 hrs